Page 9 - Pharma

Stricter regulations, pricing control slow down pharma sector growth

The fifth part of the series looks at what's ailing the pharma sector

Aurobindo recalls heartburn drug ranitidine, two others from US market

Development follows regulatory compliance issues being faced by several of its plants back home; Ranitidine taken off due to the presence of carcinogenic compound

Dr Reddy's launches cancer treatment drug Bortezomib in the US market

Bortezomib is an active ingredient similar to that of the once blockbuster cancer treatment Velcade of Millennium Pharmaceuticals

MedLife's secret sauce behind delivering medicines in less than 2 hours

MedLife has mobile apps for everyone, and a smartphone is where all the tasks happen

Indian pharma cos with bigger US presence face more FDA scrutiny: Analysts

Big entities such as Aurobindo and Dr Reddy's have been currently filing for new product approvals from multiple sites

Develop entire value chain: Dr Reddy's MD tells pharma companies

US-China trade war is going to give us a window of opportunity to expand our industry, says G V Prasad

GPAT 2020 registration process begins: Know important dates, steps to apply

GPAT is a national-level entrance examination for admission to MPharma programmes

Pharma Q2 Preview: Lack of new US approvals to overshadow domestic revival

Analysts expect a 12% growth in revenues for the sector

Pharma Monday blues: USFDA warnings drag down Glenmark, Aurobindo stocks

The Nifty Pharma index fell 3.35 per cent during the day.

Pharma PSUs likely to sign MoU with LMA for sale of surplus land

The PSUs thus are hopeful that the sale process could now be expedited

We are growing our biosimilars capacity six-fold: Lupin MD Nilesh D Gupta

We were into APIs in the US and we started finished products, said Nilesh D Gupta

Pfizer clears the decks for fresh start, looks to energise bestseller list

With six big brands that never hit the high notes in India, bundled into its venture with Mylan, the pharma major looks to energise its bestseller list

India seeks 'clear roadmap' from China to ramp up export of pharma products

Besides pharmaceuticals, India has been asking China to open up its IT market as well to ensure steady increase of Indian exports

Indian pharma industry likely to grow by 11% to $41.9 bn in FY20: Report

The industry is expected to grow at around 12 per cent and reach $20.4-$20.8 billion in the domestic market

Pharma's share in greenhouse emissions more than automotive sector: Study

More than 200 companies represent the global pharmaceutical market, yet only 25 consistently reported their direct and indirect greenhouse gas emissions in the past five years

Private pharmacy chains warming up to unbranded generic medicines

Private chains such as Generico and StayHappi Pharmacy see an opportunity and are aiming to expand rapidly over the coming months

Gujarat sees a surge in small drug firms eyeing regulated export venues

Traditionally, small and medium players had focused on the semi-regulated markets such as Latin America and Africa, among others

Boost in US sales likely to drive re-rating of Indian pharma companies

Price decline has slowed from double digits to lower single digit for Indian pharma companies in US

As generic pharma players lag, investors log into Crams companies

Acceleration in outsourcing trend is expected to help Divi's Labs, Jubilant Life and Syngene post strong revenue growth

Double-digit spend to catapult domestic pharma growth in the next 5 years

This makes India a country with one of the lowest medicine spends